Skip to content
AusGrant
Federal Forecasted GRANTS-GOV-361235

Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research

National Institutes of Health (NIH) · Competitive grant · Science & Technology

At a glance

Rigor and Reproducibility for Biomarkers in Type 1 Diabetes Clinical Research is a federal competitive grant from National Institutes of Health for the science & technology sector. Funding: 5200000. Eligible applicants: Others (see text field entitled "Additional Information on Eligibility" for clarification); Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher edu. Applications are accepted on a rolling basis. Apply via the official listing at www.grants.gov.

Amount
$5.2M total
Deadline
Rolling
Type
Competitive
Status
Forecasted

About this program

The main goal of this initiative is to establish a consortium with the overarching goal to advance the systematic identification, rigorous evaluation, validation, and assays harmonization of biomarkers that are critical to the prevention, diagnosis, and clinical management of Type 1 Diabetes (T1D). Despite significant advances in T1D research, there remains an urgent need for reliable and reproducible biomarkers that can capture the complexity of autoimmune processes, metabolic dysregulation, and individual patient variability. This initiative will leverage state-of-the-art methodologies in clinical chemistry, genomics, proteomics, metabolomics, immunophenotyping, and imaging, coupled with longitudinal patient cohorts and mining of Electronic Health Records (EHR). Within this consortium major efforts will be devoted to: 1) Harmonize established assays for biomarkers such as HbA1c and c-peptide, making sure that these assays are performed in a rigorous and reproducible manner in the clinical research community and in clinical practice. For this purpose, reference methods and materials will use a metrology approach and will be made available to the community; 2) Identify and validate other biomarkers that can be used for the prevention, diagnosis, and clinical management of T1D. It has been reported that the assays for several biomarkers routinely used in clinical research such as glucagon, amylin, chromogranin, insulin, pro-insulin and other pro-hormones are not reproducible across platforms or laboratories. For this purpose, this consortium will ensure that all assays for biomarkers routinely used in clinical research and for newly identified biomarkers are rigorously validated and assessed for reproducibility across several laboratories following a metrology approach. 

Who can apply

Others (see text field entitled "Additional Information on Eligibility" for clarification); Independent school districts; Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education; Special district governments; State governments; For profit organizations other than small businesses; Public housing authorities/Indian housing authorities; Native American tribal organizations (other than Federally recognized tribal governments); Private institutions of higher education; Public and State controlled institutions of higher education; Native American tribal governments (Federally recognized); Small businesses; Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education; County governments. Other Eligible ApplicantsIndian/Native American Tribal Governments (Other than Federally Recognized);Eligible Agencies of the Federal Government;U.S. Territory or Possession;Faith-based or Community-based Organizations;Regional Organizations;Non-domestic (non-U.S.) Entities (Foreign Institutions).

How to apply

Apply through Grants.gov using funding opportunity number RFA-DK-27-140. Register your organization (SAM.gov + Grants.gov) before the deadline, then submit the application package listed in the official notice.

Apply at official source